HBIO · Harvard Bioscience Inc

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Includes (a) the award described in footnote (1) above, (b) 12,525 shares of common stock purchased on March 16, 2026, (c) 8,475 shares of common stock purchased on March 17, 2026, and (d) 11,000 restricted stock units that fully vest on December 17, 2026.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(d) were previously reported as covering 110,000 restricted stock units. This number has been adjusted to reflect the stock split that occurred on March 13, 2026.

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Includes (a) the award described in footnote (1) above and (b) 11,000 shares of common stock beneficially owned by the Reporting Person.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and are beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.

Includes (a) the award described in footnote (1) above, (b) 10,000 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on September 5, 2026.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 2(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Includes (a) an award granting 30,000 restricted stock units (RSUs) that will vest in three equal installments on March 20, 2027, 2028, and 2029, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 5,000 shares of common stock purchased on March 16, 2026, (c) 10,000 RSUs that will vest on May 12, 2026, and (d) 2,500 shares of common stock beneficially owned by the Reporting Person.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 RSUs referenced in Footnote 1(c) were previously reported as covering 100,000 RSUs and the 2,500 shares of common stock referenced in Footnote 1(d) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

See remarks

Includes (a) 10,000 shares of common stock purchased on March 17, 2026 and (b) 11,000 restricted stock units that fully vest on September 5, 2026.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.80 to $4.95, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

Includes (a) 12,525 shares of common stock purchased on March 16, 2026, (b) 8,475 shares of common stock purchased on March 17, 2026, and (c) 11,000 restricted stock units that fully vest on December 17, 2026.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions, and the prices actually paid ranged from $4.85 to $5.00, inclusive. The reporting person has provided to the Issuer, and will provide to any security holder of the Issuer, or the Securities and Exchange Commission ("SEC") staff, upon request, information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.

Includes (a) 12,525 shares of common stock purchased on March 16, 2026, and (b) 11,000 restricted stock units that fully vest on December 17, 2026.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 11,000 restricted stock units referenced in Footnotes 3(b) and 4(c) were previously reported as covering 110,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) 10,000 restricted stock units that will vest on May 12, 2026, and (c) 2,500 shares of common stock beneficially owned by the Reporting Person.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 10,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 100,000 restricted stock units and the 2,500 shares of common stock referenced in Footnote 1(c) were previously reported as covering 25,000 shares of common stock. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Includes (a) 5,000 shares of common stock purchased on March 16, 2026, (b) an award of 50,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person and (c) an award of 50,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.

On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 50,000 restricted stock units referenced in Footnote 1(b) were previously reported as covering 500,000 restricted stock units and the 50,000 restricted stock units referenced in Footnote 1(c) were previously reported as covering 500,000 restricted stock units. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.

Represents an award of 110,000 restricted stock units that fully vest on December 17, 2026.

Represents an award of 110,000 restricted stock units that fully vest on September 5, 2026.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.

Represents forfeiture of time-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.

Represents forfeiture of time-based restricted stock units ("RSUs") granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.

Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.

This total includes 375,005 RSUs with performance based vesting conditions.

Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.

Represents an award of 500,000 RSUs with performance based vesting conditions. These RSUs will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from August 8, 2025 to the earlier of (i) July 30, 2028, and (ii) the date of a change of control, measured relative to the Russell2000 index, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these RSUs that may be earned is reported above; the maximum amount is 150% of the number reported.

Includes the awards described in footnotes (1) and (2) above.

Represents an award of 500,000 restricted stock units (RSUs) that will vest in three equal installments on August 8, 2026, 2027 and 2028, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person.

Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Includes (a) the award described in footnote (1) above and (b) 311,126 shares of common stock beneficially owned by the Reporting Person.

Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026.

Represents 100,000 restricted stock units that will vest on May 12, 2026.

Includes (a) 100,000 restricted stock units that will vest on May 12, 2026, and (b) 25,000 shares of common stock beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on March 19, 2025.

Includes (a) 8,964 RSUs that will vest on December 29, 2025, (b) 23,867 RSUs that will vest in two equal installments on March 19, 2026 and 2027, (c) 35,800 RSUs with performance based vesting conditions tied to achievements by the Company of certain performance criteria, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 64,526 shares of common stock (which includes 4,496 shares acquired on December 31, 2024 under the Issuer's Employee Stock Purchase Plan) beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on March 19, 2025.

Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 143,198 RSUs that will vest in two equal installments on March 19, 2026 and 2027, (c) 554,407 RSUs with performance based vesting conditions and (d) 2,029,770 shares of common stock beneficially owned by the Reporting Person.

Represents forfeiture of performance-based restricted stock units ("RSUs") granted to the Reporting Person on March 1, 2022 based on the final determination of the applicable performance conditions.

Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 554,407 RSUs with performance based vesting conditions and (d) 1,996,584 shares of common stock beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on December 29, 2024.

Includes (a) 117,713 RSUs that will vest on December 29, 2025, (b) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 699,772 RSUs with performance based vesting conditions and (d) 1,996,584 shares of common stock beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on December 29, 2024.

Includes (a) 8,964 RSUs that will vest on December 29, 2025, (b) 35,800 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (c) 35,800 RSUs with performance based vesting conditions tied to achievements by the Company of certain performance criteria, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 53,784 shares of common stock beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested on December 29, 2024.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit ("RSU") awards previously granted to the Reporting Person that vested in part on December 29, 2024.

Includes (a) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 RSUs that will vest on December 29, 2024, (c) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (d) 699,772 RSUs with performance based vesting conditions and (e) 1,908,749 shares of common stock beneficially owned by the Reporting Person.

This transaction was executed in multiple trades at prices ranging from $3.03 to $3.12, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Includes (a) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 RSUs that will vest on December 29, 2024, (c) 214,797 RSUs that will vest in three equal installments on March 19, 2025, 2026 and 2027, (d) 699,772 RSUs with performance based vesting conditions and (e) 1,898,749 shares of common stock beneficially owned by the Reporting Person.

Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

Includes (a) the award described in footnote (1) above and (b) 265,254 shares of common stock held by the Reporting Person.

Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

Includes (a) the award described in footnote (1) above and (b) 249,439 shares of common stock held by the Reporting Person.

Represents an award of 56,575 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025.

Includes (a) the award described in footnote (1) above and (b) 228,039 shares of common stock held by the Reporting Person.

Shares withheld by the Company solely to cover tax obligations upon the vesting of 29,880 restricted stock units ("RSUs").

Includes (a) the awards described in footnotes (2) and (3) above, (b) 17,928 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 11,171 RSUs that will vest on December 29, 2024, (d) 25,862 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 42,177 shares of common stock beneficially owned by the Reporting Person.

The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.

Includes (a) the awards described in footnotes (1) and (2) above, (b) 235,427 RSUs that will vest in two equal installments on December 29, 2024 and 2025, (c) 52,346 RSUs that will vest on December 29, 2024, (d) 484,975 RSUs with performance based vesting conditions tied to relative total shareholder return and (e) 1,878,749 shares of common stock beneficially owned by the Reporting Person.

The number of RSUs represents the target number of RSUs that may be earned based on achievement by the Company of certain performance criteria. The actual number of RSUs awarded may vary between 0% and 150% of the target, depending on the Company's performance. The performance period will end on December 31, 2026.

Represents an award of restricted stock units ("RSUs") that will vest in three equal installments on March 19, 2025, 2026, and 2027.

Represents an award of RSUs that will vest in three equal installments on March 19, 2025, 2026, and 2027.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person that vested on December 31, 2023.

Includes (a) 235,427 restricted stock units that will vest in two equal installments on December 29, 2024 and 2025, (b) 52,346 restricted stock units that will vest on December 29, 2024, (c) 484,975 restricted stock units with performance based vesting conditions tied to relative total shareholder return and (d) 1,878,749 shares of common stock beneficially owned by the Reporting Person.

The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit awards previously granted to the Reporting Person that vested on December 29, 2023.